Stocks and Investing
Stocks and Investing
Fri, April 12, 2024
[ Fri, Apr 12th 2024
] - WOPRAI
[ Fri, Apr 12th 2024
] - WOPRAI
[ Fri, Apr 12th 2024
] - WOPRAI
[ Fri, Apr 12th 2024
] - WOPRAI
Thu, April 11, 2024
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
[ Thu, Apr 11th 2024
] - WOPRAI
Andrew Fein Reiterated (AMLX) at Strong Buy and Held Target at $8 on, Apr 11th, 2024
Andrew Fein of HC Wainwright & Co., Reiterated "Amylyx Pharmaceuticals, Inc." (AMLX) at Strong Buy and Held Target at $8 on, Apr 11th, 2024.
Andrew has made no other calls on AMLX in the last 4 months.
There are 5 other peers that have a rating on AMLX. Out of the 5 peers that are also analyzing AMLX, 3 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Chris Shibutani of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $4 on, Monday, March 11th, 2024
- Marc Goodman of "Leerink Partners" Downgraded from Buy to Hold on, Monday, March 11th, 2024
- Umer Raffat of "Evercore ISI Group" Downgraded from Buy to Hold on, Friday, March 8th, 2024
These are the ratings of the 2 analyists that currently disagree with Andrew
- Neena Bitritto-Garg of "Deutsche Bank" Maintained at Strong Buy with Decreased Target to $8 on, Monday, March 11th, 2024
- Graig Suvannavejh of "Mizuho" Reiterated at Strong Buy with Increased Target to $32 on, Friday, March 8th, 2024
Contributing Sources